Latest Breaking News On - Well tolerated - Page 1 : vimarsana.com

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Bexotegrast at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320.

United statesGideon hirshfieldClin gastroenterol hepatolKrisv kowdleyChristopher keenanTerry hornerWashington state universityElsons floyd college of medicineCorporate communicationsDrug administrationLiver instituteEuropean medicines agencyPliant therapeutics incUniversity of torontoClinical development nextGlobenewswire inc

Pliant Therapeutics Announces Positive Safety and

Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns.

United statesGideon hirshfieldChristopher keenanClin gastroenterol hepatolTerry hornerKrisv kowdleyUniversity of torontoCorporate communicationsLiver instituteClinical development nextDrug administrationEuropean medicines agencyPliant therapeutics incEnhanced liver fibrosisChief medical officerWell tolerated

Pliant Therapeutics Announces Positive Safety And Exploratory Efficacy Data From The INTEGRIS-PSC Phase 2A Trial Of Bexotegrast 320 Mg In Patients Wit

Pliant Therapeutics Announces Positive Safety And Exploratory Efficacy Data From The INTEGRIS-PSC Phase 2A Trial Of Bexotegrast 320 Mg In Patients Wit
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesClin gastroenterol hepatolTerry hornerChristopher keenanKrisv kowdleyGideon hirshfieldPliant therapeutics incEuropean medicines agencyDrug administrationCorporate communicationsUniversity of torontoLiver instituteClinical development nextEnhanced liver fibrosisChief medical officerWell tolerated

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesKrisv kowdleyGideon hirshfieldClin gastroenterol hepatolChristopher keenanTerry hornerDrug administrationEuropean medicines agencyClinical development nextUniversity of torontoPliant therapeutics incLiver instituteCorporate communicationsEnhanced liver fibrosisChief medical officerWell tolerated

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNeal walkerDouglas manionAclaris therapeutics incExchange commissionStatistically significant resultPrimary efficacy endpointSystemic exposure supportsWell toleratedAclari chairmanEczema areaSeverity indexInvestigator global assessment treatment successAclari chief executiveAclaris therapeuticsPrivate securities litigation reform act